Lorna Villafuentes-Vidal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lorna Villafuentes-Vidal has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Velez-Herrera
University Center for Health Sciences, University of Guadalajara, Guadalajara 44340, Mexico
1 shared publication - Carmen Rubio
Neurophysiology Department, National Institute of Neurology and Neurosurgery, Mexico City 14269, Mexico
1 shared publication - Edson Castro-Velázquez
Faculty of Medicine, University of Guadalajara, Guadalajara 44340, Mexico
1 shared publication - Elisa Taddei
Department of Neurophysiology, Instituto Nacional de Neurología y Neurocirugía, Mexico City 14269, Mexico
1 shared publication - Moisés Rubio-Osornio
Department of Neurochemistry, National Institute of Neurology and Neurosurgery, Mexico City 14269, Mexico
1 shared publication - Nadia Fernanda Esteban-Román
Biological Sciences and Health Division, Department of Biological Systems, Xochimilco Campus, Metropolitan Autonomous University, Mexico City 04960, Mexico
1 shared publication
Latest Publications
- Open Access
- 19 August 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (8) , 884
Redox-Regulated Pathways in Glioblastoma Stem-like Cells: Mechanistic Insights and Therapeutic Implications
Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by rapid proliferation, invasiveness, therapeutic resistance, and an immunosuppressive tumor microenvironment. A subpopulation of glial stem-like cells (GSCs) within GBM tumors contributes significantly to tumor initiation, progression, and relapse, displaying remarkable adaptability to oxidative stress and metabolic reprogramming. Recent evidence implicates the atypical kinases RIOK1 and RIOK2 in promoting GBM growth and proliferation through their interaction with oncogenic pathways such as AKT and c-Myc. Concurrently, the redox-sensitive Nrf2/Keap1 axis regulates antioxidant defenses and supports GSC survival and chemoresistance. Additionally, aberrant activation of the canonical Wnt/β-catenin pathway in GSCs enhances their self-renewal, immune evasion, and resistance to standard therapies, particularly under oxidative stress conditions. This review integrates current knowledge on how redox homeostasis and key signaling pathways converge to sustain GSC maintenance and GBM malignancy. Finally, we discuss emerging redox-based therapeutic strategies designed to target GSC resilience, modulate the tumor immune microenvironment, and surmount treatment resistance.
- 19 August 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (8) , 884
Open AccessRedox-Regulated Pathways in Glioblastoma Stem-like Cells: Mechanistic Insights and Therapeutic Implications
Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by rapid proliferation, invasiveness, therapeutic resistance, and an immunosuppressive tumor microenvironment. A subpopulation of glial stem-like cells (GSCs) within GBM tumors contributes significantly to tumor initiation, progression, and relapse, displaying remarkable adaptability to oxidative stress and metabolic reprogramming. Recent evidence implicates the atypical kinases RIOK1 and RIOK2 in promoting GBM growth and proliferation through their interaction with oncogenic pathways such as AKT and c-Myc. Concurrently, the redox-sensitive Nrf2/Keap1 axis regulates antioxidant defenses and supports GSC survival and chemoresistance. Additionally, aberrant activation of the canonical Wnt/β-catenin pathway in GSCs enhances their self-renewal, immune evasion, and resistance to standard therapies, particularly under oxidative stress conditions. This review integrates current knowledge on how redox homeostasis and key signaling pathways converge to sustain GSC maintenance and GBM malignancy. Finally, we discuss emerging redox-based therapeutic strategies designed to target GSC resilience, modulate the tumor immune microenvironment, and surmount treatment resistance.